Abliva AB (publ) (0QDU.L)
| Previous close | 0.2245 |
| Open | 0.2510 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 0.2510 - 0.2510 |
| 52-week range | 0.2050 - 0.3145 |
| Volume | |
| Avg. volume | 9,043 |
| Market cap | N/A |
| Beta (5Y monthly) | 1.24 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.3130 |
| Earnings date | 22 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireAbliva Announces Positive Interim Analysis of the FALCON Study for KL1333 in Primary Mitochondrial Disease
- Independent committee confirms FALCON study is powered for potential success with both alternative endpoints passing futility- -Committee confirms strong safety profile of KL1333- - Abliva to host conference call and webcast on Friday 19 July at 4:30 pm CET / 10:30 am ET – LUND, Sweden, July 18, 2024 (GLOBE NEWSWIRE) -- Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, today announced a positive out
- GlobeNewswire
Abliva to Host Virtual KOL Event on KL1333 in Primary Mitochondrial Disease on May 21, 2024
LUND, Sweden, May 13, 2024 (GLOBE NEWSWIRE) -- Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, today announced that it will host a virtual KOL event on Tuesday, May 21, 2024 at 10:00 AM ET / 4:00 PM CET, featuring Amel Karaa, MD (Massachusetts General Hospital), who will discuss the unmet medical need and current treatment landscape for patients with primary mitochondrial disease. There are currentl
